Market Research Logo

Dermatological Drugs Market Forecast 2018-2028

Dermatological Drugs Market Forecast 2018-2028

The revenue of the dermatological drugs market in 2017 is estimated at $26.07bn and is expected to grow at a CAGR of 5.8% in the first half of the forecast period. Psoriasis drugs segment accounted for the largest share of the market in 2017, this segment accounted for 36% of the global dermatological drugs market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 333-page report you will receive 124 tables and 147 figures– all unavailable elsewhere.

The 333-page report provides clear detailed insight into the dermatological drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

  • Dermatological drugs market forecasts from 2018-2028
  • This report also breaks down the revenue forecast for the main submarkets:
  • Psoriasis
  • Skin Infections
  • Acne
  • Dermatitis
  • Analysis of the Psoriasis drugs market. Revenue forecasts to 2028 are provided for the following drugs:
  • Humira
  • Stelara
  • Enbrel
  • Remicade
  • Taltz
  • Otezla
  • Cosentyx
  • Analysis of the Skin Infections drugs market. Revenue forecasts to 2028 are provided for the following drugs:
  • Cubicin
  • Zyvox
  • Valtrex
  • Canesten
  • Lamisil
  • Bactroban
  • Analysis of the Acne drugs market. Revenue forecasts to 2028 are provided for the following drugs:
  • Solodyn
  • Epiduo
  • Claravis
  • Aczone
  • Differin
  • Abscorical/Epirus
  • Ziana
  • Doryx
  • Analysis of the Dermatitis drugs market. Revenue forecasts to 2028 are provided for the following drugs:
  • Bepanthen/Bepanthol
  • Protopic
  • Dermovate
  • Elocon
  • This report provides individual revenue forecasts to 2028 for these regional and national markets:
  • North America: US & Canada
  • Europe: Germany, France, UK, Italy, Spain, Rest of Europe
  • Asia-Pacific: China, Japan, India, Rest of Asia-Pacific
  • Latin America: Brazil, Mexico, Rest of Latin America
  • Middle East & Africa (MEA): Saudi Arabia, South Africa, Rest of MEA
Each regional market is further segmented by indication: psoriasis, skin infection, acne, dermatitis and others.
  • This report provides discussion on pipeline products in various stages of clinical trials and regulatory approval.
  • Our study includes SWOT analysis and Porter’s Five Force analysis of the dermatological drugs market.
  • Our study discusses the selected leading companies that are the major players in the dermatological drugs market:
  • AbbVie
  • Amgen
  • Bayer AG
  • Galderma (Nestle Skin Health S.A.)
  • GlaxoSmithKline (GSK)
  • Johnson & Johnson
  • LEO Pharma
  • Merck & Co, Inc.
  • Novartis
  • Pfizer
Our new report discusses issues and events affecting the dermatological drugs market:
  • Highly fragmented and competitive market with significant variations in different geographic regions
  • Changing political and regulatory landscape changing the prospects of future products and reimbursement opportunities
  • Future paradigm-shifting pipeline products
  • Patent expirations
  • Launches of new drug categories
  • Biosimilars approvals, Biosimilars interchangeability, Biosimilars guidance
Visiongain’s study is intended for anyone requiring commercial analyses for the dermatological drugs market. You find data, trends and predictions.

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

The publisher is using a password system to access all reports. Single user (non-printable) and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.


1. Report Overview
1.1 Global Dermatological Drugs Market Overview
1.2 Overview of Findings
1.3 Structure of the Report
1.4 Global Dermatological Drugs Market Segmentation
1.5 Why You Should Read This Report
1.6 How This Report Delivers
1.7 Key Questions Answered by This Analytical Report
1.8 Who is This Report For?
1.9 Methodology
1.10 Associated Visiongain Reports
1.11 About Visiongain
2. Introduction to Dermatological Drugs
2.1 The Pharmaceutical Industry: A Brief Introduction
2.2 An Introduction to Dermatology
2.2.1 The Structure of Skin, Hair, and Nails
2.2.2 Hair and Nails
2.2.3 Sweat and Sebaceous Glands
2.2.4 Functions of the Skin
2.3 Common Skin Diseases
2.3.1 Acne: The Most Common Skin Disease
2.3.1.1 Acne: Epidemiology
2.3.1.2 Acne: Causes and Pathogenesis
2.3.1.3 Acne: Treatment
2.3.2 Dermatitis: Inflammation of the Skin
2.3.2.1 Atopic Dermatitis
2.3.2.2 Contact Dermatitis
2.3.2.3 Seborrhoeic Dermatitis
2.3.2.4 Nummular Dermatitis
2.3.2.5 Perioral Dermatitis
2.3.3 Psoriasis: A Complex Multi-Factorial Disease
2.3.4 Rosacea: Vascular Instability
2.3.5 Alopecia: Excessive Shedding of Hair
2.4 Skin Infections: A Serious Healthcare Threat
2.4.1 Bacterial Skin Infections
2.4.2 Fungal Skin Infections
2.4.3 Viral Skin Infections
2.5 Common Skin Treatments
2.5.1 Creams and Semisolid Emulsions
2.5.2 Ointments
2.5.3 Lotions
2.5.4 Solutions
2.5.5 Occlusive Therapy
2.5.6 Cleansing Agents
2.5.7 Powders and Hydrophilic Polymer
2.5.8 Anti-Infective Agents
2.5.9 Anti-Inflammatory Agents
2.6 Phases of Clinical Trials
2.7 Dermatological Drugs: Market Definition in this Report
3. Global Dermatological Drugs Market, by Drugs Class 2018-2028
3.1 The Global Dermatological Drugs Market: Market Overview
3.2 Categorisation of the Global Dermatological Drugs Market
3.3 The Global Dermatological Drugs Market in 2017
3.4 The Global Dermatological Drugs Market: Market Forecast 2018-2028
3.5 Changing Market Shares by Segment 2018-2028
4. The Psoriasis Drugs Market: Market Analysis and Forecast 2018-2028
4.1 Psoriasis Treatments: The Dominance of Biologics
4.1.1 Leading Products in the Psoriasis Drugs Market, 2017
4.2 Psoriasis: Market Trends and Developments, 2017
4.2.1 Biological Drugs in Psoriasis Treatment: A Brief Overview
4.2.2 Issues around Patent Protection, the Threat of Biosimilars and Pricing
4.2.3 Biosimilars and Interchangeables
4.2.3.1 Extrapolation of indications
4.2.3.2 Biosimilar interchangeability in the EU
4.2.3.3 Biosimilar guidance in the US
4.2.3.4 The Disadvantages of Biologics in Psoriasis Treatment
4.3 Psoriasis Drugs: Market Forecast 2018-2028
4.3.1 Psoriasis Drugs: Changing Market Shares by Leading Drugs 2018-2028
4.4 Leading Drugs Used in the Treatment of Psoriasis
4.4.1 Humira (adalimumab) - AbbVie
4.4.1.1 Humira: Historical Sales Analysis, 2010-2017
4.4.1.2 Humira: Sales Forecast 2018-2028
4.4.1.3 Future Prospects for Biosimilar Versions of Humira
4.4.2 Stelara (ustekinumab) – Johnson & Johnson
4.4.2.1 Stelara New Market Leader, Ahead of Humira
4.4.2.2 Stelara: Historical Sales Analysis, 2010-2017
4.4.2.3 Stelara: Sales Forecast 2018-2028
4.4.2.4 Intensifying Competition for Stelara
4.4.3 Enbrel (etanercept) - Amgen/ Pfizer/ Takeda
4.4.3.1 Enbrel: Co-Promotions and Marketing Rights
4.4.3.2 Enbrel: Historical Sales Analysis, 2009-2017
4.4.3.3 Enbrel: Patent Expiries and Potential Competition, 2018-2028
4.4.3.4 Patent Litigation with Sandoz Over Enbrel
4.4.3.5 Enbrel: Sales Forecast 2018-2028
4.4.3.6 Enbrel Auto-injector Pens: A Driver of Growth in Recent Years
4.4.3.7 Competition from Other Drugs
4.4.3.8 Biosimilar Competition for Enbrel
4.4.4 Remicade (infliximab) – Johnson & Johnson
4.4.4.1 Remicade: Historical Sales Analysis, 2009-2017
4.4.4.2 Remicade: Patent Expiries and Potential Competition, 2018-2028
4.4.4.3 Remicade: Sales Forecast 2018-2028
4.4.5 Taltz (ixekizumab) – Eli Lilly
4.4.5.1 Taltz: Sales Forecast 2018-2028
4.4.6 Otezla (apremilast) – Celgene
4.4.6.1 Otezla: Sales Forecast 2018-2028
4.4.7 Cosentyx (secukinumab) - Novartis
4.4.7.1 Cosentyx: Sales Forecast 2018-2028
4.4.8 Other Psoriasis Drugs
4.4.8.1 Cimzia (certolizumab) - UCB
4.4.8.2 Sorilux (calcipotriene foam) - GSK
4.4.8.3 Siliq (brodalumab) - AstraZeneca/ LEO Pharma
4.4.8.4 Other Psoriasis Drugs: Sales Forecast 2018-2028
4.5 Psoriasis Drugs Market: Summary
5. Skin Infection Drugs Market: Market Analysis and Forecast 2018-2028
5.1 Skin Infection Drugs: Abundant Growth Opportunities
5.1.1 Leading Products in the Skin Infection Drugs Market, 2017
5.2 Skin Infection Drugs: Market Forecast 2018-2028
5.2.1 Skin Infection: Changing Market Shares by Leading Drugs 2018-2028
5.3 Leading Drugs Used in the Treatment of Skin Infections
5.3.1 Cubicin (daptomycin) - Cubist Pharmaceuticals/ Merck & Co
5.3.2 Acquisition by Merck & Co
5.3.3 Generic Competition for Cubicin
5.3.4 Cubicin: Sales Forecast 2018-2028
5.3.5 Lifecycle Management Strategies for Cubicin
5.4 Zyvox (linezolid) - Pfizer
5.4.1 Zyvox: Historical Sales Analysis, 2010-2017
5.4.2 Zyvox: Sales Forecast 2018-2028
5.4.3 The Threats to Zyvox Sales from Competing New Drugs
5.5 Canesten (clotrimazole) - Bayer
5.5.1 Canesten: Historical Sales Analysis, 2011-2017
5.5.2 Canesten: Sales Forecast 2018-2028
5.6 Valtrex (valaciclovir) - GSK
5.6.1 Valtrex: Historical Sales Analysis, 2010-2017
5.6.2 Valtrex: Sales Forecast 2018-2028
5.7 Bactroban (mupirocin) - GSK
5.7.1 Bactroban: Historical Sales Analysis, 2010-2013
5.7.2 Bactroban: Sales Forecast 2018-2028
5.8 Lamisil (terbinafine) - Novartis
5.8.1 Lamisil Patent Expiry
5.8.2 Lamisil Sales Affected by Novartis Manufacturing Problems
5.8.3 Lamisil: Sales Forecast 2018-2028
5.9 Other Skin Infection Drugs
5.9.1 Dalvance (dalbavancin) - Durata Therapeutics
5.9.2 Jublia (efinaconazole) - Valeant
5.9.3 Kerydin (tavaborole) - Anacor
5.9.4 Sivextro (tedizolid) – Cubist Pharmaceuticals
5.9.5 Zovirax (acyclovir) - Valeant/GSK
5.9.5.1 Valeant Acquires Zovirax in US and Canada
5.9.5.2 Mylan‟s Generic Zovirax and Actavis‟ Authorised Generic
5.9.6 Other Skin Infection Drugs: Sales Forecast 2018-2028
5.10 Skin Infection Drugs: Market Summary
6. Acne Drugs Market: Market Analysis and Forecast 2018-2028
6.1 Acne Drugs: A Diversified Market
6.1.1 Leading Products in the Acne Drugs Market, 2017
6.2 Acne Drugs Market: Recent Trends and Developments
6.2.1 The Rise of Combination Therapies in Acne Treatment
6.2.2 Oral Contraceptives in Treating Acne
6.2.3 The Threat of Generic Competition in the Acne Drugs Market
6.3 Acne Drugs: Market Forecast 2018-2028
6.3.1 Acne Drugs: Changing Market Shares by Leading Drugs 2018-2028
6.4 Leading Drugs in the Acne Drugs Market
6.4.1 Epiduo (adapalene/benzoyl peroxide) – Galderma/ Nestlé Skin Health
6.4.1.1 Epiduo: Sales Forecast 2018-2028
6.4.1.2 Galderma Settlement Agreement over Generic Epiduo
6.4.1.3 Paediatric Approval for Epiduo
6.4.2 Solodyn (minocycline) - Valeant
6.4.2.1 Solodyn: Sales Forecast 2018-2028
6.4.2.2 Antitrust Action over Solodyn Pay-For-Delay Deals
6.4.2.3 Impax and Medicis Collaborating on Advanced Solodyn
6.4.2.4 Medicis and Lupin Settle
6.4.3 Claravis (isotretinoin) - Teva
6.4.3.1 Claravis: Sales Forecast 2018-2028
6.4.4 Aczone (dapsone) - Allergan
6.4.4.1 Aczone: Sales Forecast 2018-2028
6.4.5 Differin (adapalene) – Galderma/ Nestlé Skin Health
6.4.5.1 Recent Generic Competition to Differin
6.4.5.2 Differin: Sales Forecast 2018-2028
6.4.5.3 Adapalene Gel to be Available OTC in the US
6.4.5.4 Federal Circuit Court Invalidates Differin Patents
6.4.6 Absorica/Epuris (CIP-isotretinoin) – Cipher/Sun Pharma
6.4.6.1 Absorica/Epuris: Sales Forecast 2018-2028
6.4.7 Ziana (clindamycin/tretinoin) – Valeant Pharmaceuticals International
6.4.7.1 Valeant‟s Patent Settlement with Actavis over Ziana
6.4.7.2 Ziana: Sales Forecast 2018-2028
6.4.8 Doryx (doxycycline) – Actavis/Mayne Pharma
6.4.8.1 Lifecycle Management Strategies for Doryx
6.4.8.2 Divestment Agreement with Mayne Pharma
6.4.8.3 Generic Competition for Doryx
6.4.8.4 Doryx: Sales Forecast 2018-2028
6.4.9 Other Acne Drugs
6.4.9.1 Acanya (clindamycin/benzoyl peroxide) – Dow
6.4.9.1.1 Actavis Claims First-to-File Exclusivity for its Acanya
6.4.9.1.2 Legal Battles Involving Dow/Valeant, Perrigo, and Watson
6.4.9.2 Amnesteem (isotretinoin) - Mylan
6.4.9.2.1 Amnesteem: Financial Analysis
6.4.9.3 Diane (cyproterone/ethinyl estradiol) - Bayer
6.4.9.4 Duac (clindamycin/benzoyl peroxide) –
6.4.9.5 Veltin (tretinoin/clindamycin) - GSK
6.4.9.6 Other Acne Drugs: Sales Forecast 2018-2028
6.5 Acne Drugs: Market Summary
7. Dermatitis Drugs Market: Market Analysis and Forecast 2018-2028
7.1 Dermatitis Drugs: High Generic Penetration
7.1.1 Leading Products in the Dermatitis Drugs Market, 2017
7.2 Dermatitis Drugs: Market Forecast 2018-2028
7.2.1 Dermatitis Drugs: Changing Market Shares by Leading Drugs 2018-2028
7.3 Leading Drugs in the Dermatitis Drugs Market
7.3.1 Bepanthen (dexpanthenol)/ Bepanthol - Bayer
7.3.1.1 Bepanthen: Sales Forecast 2018-2028
7.3.2 Elocon (mometasone) - Merck & Co
7.3.2.1 Elocon: Sales Forecast 2018-2028
7.3.3 Protopic (tacrolimus) – LEO Pharma
7.3.3.1 Protopic Benefits from Expanded Indication
7.3.3.2 Generic Competition for Protopic
7.3.3.3 Protopic: Sales Forecast 2018-2028
7.3.4 Dermovate -GSK
7.3.4.1 Dermovate: Sales Forecast 2018-2028
7.3.5 Other Dermatitis Drugs: Sales Forecast 2018-2028
7.4 Dermatitis Drugs: Market Outlook
8. Leading National Markets 2018-2028
8.1 Geographical Breakdown of the World Dermatological Drugs Market
8.2 World Dermatological Drugs Market: Regional Forecast 2018-2028
8.2.1 How Will Regional Market Shares Change to 2028?
9. North America Dermatological Drugs Market 2018-2028
9.1. U.S. Dermatological Drugs Market: Trends and Developments
9.1.1. Obamacare Repeal
9.1.2. Legislative Environment Stimulating Biosimilars
9.1.3 Biosimilar Interchangeability guidance in the US
9.1.4 US Dermatological Drugs Market: Market Forecast 2018-2028
9.2. Canada Dermatological Drugs Market: Trends and Developments
10. Europe Dermatological Drugs Market 2018-2028
10.1 Europe Markets: Changing Market Shares by Country, 2018-2028
10.2 Germany
10.2.1 Germany Dermatological Drugs Market: Market Forecast 2018-2028
10.3. France Dermatological Drugs Market Forecast 2018-2028
10.4. U.K.
10.4.1 The Impact of Brexit On the Dermatological Drugs
10.4.2 Pricing and Reimbursement
10.4.3 New Regulatory Body and Clinical Trials
10.4.4 Patent Protection
10.4.5 Research and Funding
10.4.6. U.K. Dermatological Drugs Market Forecast 2018-2028
10.5 Italy
10.5.1 Italy Dermatological Drugs Market Forecast 2018-2028
10.6. Spain Dermatological Drugs Market Forecast 2018-2028
10.7. Rest of Europe Dermatological Drugs Market Forecast 2018-2028
10.7.1 Russia
10.7.1.1 Pharma2020 Strategy - Healthcare and Industry Reform
11. Asia-Pacific Dermatological Drugs Market 2018-2028
11.1 China
11.1.1 Expansion of Healthcare Coverage and Reimbursement in China
11.1.2 Improving Public Perception of Dermatology in China
11.1.3 Price Controls and the Anhui Model
11.1.4 Chinese Dermatological Drugs Market Forecast 2018-2028
11.2. Japan Dermatological Drugs Market: Trends and Developments
11.2.1 The Cost of Treatment in Japan
11.2.2 Japanese Pharmaceutical Industry Regulatory Reform
11.2.3 Japanese Dermatological Drugs Market Forecast
11.3. India
11.3.1 The Effects of the Drug Prices Control Order of 2013
11.3.2 India‟s Expansion of Healthcare Provision
11.3.3 Revised Biosimilar Guidelines
11.3.4 Indian Dermatological Drugs Market Forecast 2018-2028
11.4. Rest of Asia-Pacific Dermatological Drugs Market: Trends and Developments
12. Latin America Dermatological Drugs Market 2018-2028
12.1 Brazil
12.1.1 The Growth in Brazil‟s Healthcare Landscape
12.1.2 Clearer Access to Medicines in Brazil
12.1.3 Brazil Dermatological Drugs Market Forecast 2018-2028
12.2. Mexico Dermatological Drugs Market: Trends and
12.3. Rest of Latin America Dermatological Drugs Market: Trends and Developments
13. Middle East & Africa Dermatological Drugs Market 2018-2028
13.1. Saudi Arabia Dermatological Drugs Market Forecast 2018-2028
13.2. South Africa Dermatological Drugs Market Forecast 2018-2028
13.3. Rest of Middle East & Africa Dermatological Drugs Market Forecast 2018-2028
14. Leading Companies in the Dermatological Drugs Market
14.1. Galderma (Nestle Skin Health S.A.)
14.1.1 Galderma: Dermatological Drugs Product Portfolio
14.1.2 Financial Overview
14.1.3 Recent Transactions Summary
14.2. Johnson & Johnson
14.2.1 Johnson & Johnson: Dermatological Drugs Product Portfolio
14.2.2 Financial Overview
14.2.2.1 Pipeline, 2018
14.2.3 Recent Transactions Summary
14.3. GlaxoSmithKline plc
14.3.1 GlaxoSmithKline plc: Dermatological Drugs Portfolio
14.3.2 GlaxoSmithKline plc: Financial Overview
14.3.3 GlaxoSmithKline plc: Recent Transactions Summary
14.4. Pfizer, Inc.
14.4.1 Pfizer, Inc.: Dermatological Drugs Portfolio
14.4.2 Pfizer, Inc.: Financial Overview
14.4.3 Pfizer, Inc.: Recent Developments
14.4.4 Pfizer: Dermatological Drugs Development Pipeline, 2018
14.5.LEO Pharma A/S
14.5.1 LEO Pharma A/S.: Dermatological Drugs Product Portfolio
14.5.2 Financial Overview
14.5.3 Recent Transactions Summary
14.6. AbbVie Inc.
14.6.1 AbbVie Inc.: Dermatological Drugs Product Portfolio
14.6.2 Financial Overview
14.6.3 Recent Transactions Summary
14.7. Novartis AG
14.7.1 Novartis: Dermatological Drugs Portfolio
14.7.2 Novartis: Financial Overview
14.7.3 Novartis: Recent Developments
14.8. Amgen, Inc.
14.8.1 Amgen, Inc.: Dermatological drugs Portfolio
14.8.2 Financial Overview
14.8.3 Recent Transactions Summary
14.9 Merck & Co., Inc.
14.9.1 Merck & Co., Inc.: Dermatological Drugs Portfolio
14.9.2 Merck & Co., Inc.: Financial Overview
14.9.3 Merck & Co., Inc.: Recent Transactions Summary
14.10 Bayer AG
14.10.1 Bayer AG: Dermatological Drugs Portfolio
14.10.2 Bayer AG: Financial Overview
14.10.3 Bayer AG: Recent Transactions Summary
15. Dermatological Drugs: Research and Development Pipeline, 2018-2028
15.1 Innovative Products Currently in Development Will Drive Growth
15.1.1 New Technology in R&D Pipeline Activities
15.1.1.1 Reformulation
15.1.1.2 Combination Treatments
15.1.1.3 New Mechanisms and Drug Delivery Technologies
15.1.1.4 Potential Market Entrants
15.2 Psoriasis Drugs Development Pipeline, 2017
15.2.1 Psoriasis Drugs in Phase 3 Development or
15.2.1.2 CF101 (Piclidenoson) - Can-Fite BioPharma
15.2.2 Psoriasis Drugs in Phase 2 Development
15.2.2.1 LY3009104 (baricitinib) - Incyte/ Eli Lilly
15.2.2.2 PH-10 (Rose Bengal) – Provectus
15.2.3 Psoriasis Drugs in Phase 1 and Pre-Clinical
15.3 Skin Infection Drugs Development Pipeline, 2018
15.3.1 Drugs in Phase 3 Development for Skin Infections
15.3.1.1 Baxdela (delafloxacin) - Melinta Pharmaceuticals
15.3.1.2 NB-001 - NanoBio Corporation
15.3.1.3 Luliconazole - Topica Pharmaceuticals
15.3.2 Drugs in Phase 2 Development for Skin Infections
15.3.3 Drugs in Phase 1 and Preclinical Pipeline for Skin Infections
15.4 Acne Drugs Development Pipeline, 2017
15.4.1 Drugs in Phase 3 Development for Acne
15.4.1.2 Visonac (photodynamic therapy) - Photocure
15.4.2 Drugs in Phase 2 Development for Acne
15.4.3 Drugs in Phase 1 and Pre-Clinical Development for Acne
15.4.4 A Possible Vaccine for Acne
15.5 Dermatitis Drugs Development Pipeline, 2017
15.5.1 Drugs in Phase 3 Development for Dermatitis
15.5.1.1 Toctino (alitretinoin) - GSK
15.5.1.2 Dermadexin and Pruridexin (P3CGM) – Cipher
15.5.1.3 Dexeryl Cream (glycerol/paraffin emollient) – Pierre
15.5.1.4 REGN668/SAR231893 (dupilumab) -
15.5.2 Drugs in Phase 2 Development for Dermatitis
15.5.3 Drugs in Phase 1 and Preclinical Stages of Development for Dermatitis
15.6 Other Dermatological Drugs Development Pipeline, 2017
15.6.1 Other Dermatological Drugs: Filed or Recently
15.6.1.1 Actikerall (fluorouracil/salicylic acid) - Almirall
15.6.1.2 Ameluz (5-ALA photodynamic therapy) - Biofrontera
15.6.1.3 Mirvaso (brimonidine) - Galderma
15.6.1.4 Picato (ingenol mebutate) - LEO Pharma
15.6.1.5 Xolair (omalizumab) - Novartis/ Roche
15.6.2 Other Dermatological Drugs: Phase 3 Pipeline
15.6.2.1 CD5024 (ivermectin) - Galderma
15.6.2.2 SR-T100 gel (Solanum incanum extract) - G&E
15.6.3 Other Dermatological Drugs: Phase 2 Pipeline
16. Qualitative Analysis of the Dermatological Drugs Market, 2018-2028
16.1 Market Factors Influencing Dermatological Drugs
16.2 SWOT Analysis of the Global Dermatological Drugs Market, 2018-2028
16.2.1 Strengths
16.2.1.1 The High Unmet Clinical Need in Dermatology
16.2.1.2 A Healthy Pipeline of Development-Stage Products
16.2.1.3 Strong Industry-Physician Relationships
16.2.2 Weaknesses
16.2.2.1 Limited Efficacy and Adverse Effects May Impact
16.2.2.2 Patient Adherence – A Major Challenge to
16.2.2.3 Impending Patent Expiries and the Challenges
16.2.3 Opportunities
16.2.3.1 The High-Growth Sectors in Dermatology
16.2.3.2 Personalised Dermatology: Technological Advances in Genomics
16.2.3.3 Advances in Topical Drug Delivery Methods Offers
16.2.3.4 Consolidation within Dermatology – Opportunity for Synergistic Growth?
16.2.4 Threats
16.2.4.1 Uncertainty Surrounding Reimbursement and
16.2.4.2 The Rising Cost of Research and Development
16.2.4.3 Downward Pressures on Drug Prices
16.3 Porter’s Five Force Analysis of the Global Dermatological Drugs Market, 2018-2028
16.3.1 Threat of New Entrants
16.3.2 Threat of Substitutes
16.3.3 Rivalry among Competitors
16.3.4 Power of Buyers
16.3.5 Power of Suppliers
17. Conclusions
17.1 Overview of Current Market Conditions and Market Forecast, 2018-2028
17.2 Leading Sectors in Dermatological Drugs in 2017
17.3 Leading Regions in the Dermatological Drugs Market in 2017
17.4 Future Outlook for the Various Sectors within the Dermatological Drugs Market, 2018-2028
17.5 What Does the Future Hold for Dermatological Drugs?
Appendices
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form
List of Tables
Table 2.1 Clinical Trial Phases, 2017
Table 3.1 Global Dermatological Drugs Market by Drugs Class: Revenue ($bn), and Market Share (%), 2017
Table 3.2 Global Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
Table 3.3 Global Dermatological Drugs Market by Drugs Class: CAGR (%), 2018-2022, 2022-2028, 2018-2028
Table 4.1 Global Psoriasis Drugs Market by Drugs Class: Revenue ($bn), and Market Share (%), 2017
Table 4.2 Global Psoriasis Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
Table 4.3 Global Psoriasis Drugs Market by Drugs Class: CAGR (%), 2018-2022, 2022-2028, 2018-2028
Table 4.4 Global Humira Market Forecast: Revenues ($bn) AGR (%), 2010-2017
Table 4.5 Global Humira Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 4.6 Global Stelara Market Forecast: Revenues ($bn) AGR (%), 2010-2017
Table 4.7 Global Stelara Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 4.8 Global Enbrel Market Forecast: Revenues ($Bn) AGR (%), 2009-2017
Table 4.9 Global Enbrel Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 4.10 Global Remicade Market Forecast: Revenues ($bn) AGR (%), 2009-2017
Table 4.11 Global Remicade Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 4.12 Global Taltz Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 4.13 Global Otezla Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 4.14 Global Cosentyx Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 4.15 Global Others Market Forecast: Revenues ($Bn) AGR (%), CAGR (%), 2016-2028
Table 5.1 Global Skin Infection Drugs Market by Drugs Class: Revenue ($bn), and Market Share (%), 2017
Table 5.2 Skin Infection Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
Table 5.3 Global Skin Infection Drugs Market by Drugs Class: CAGR (%), 2018-2022, 2022-2028, 2018-2028
Table 5.4 Global Cubicin Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 5.5 Global Zyvox Market Forecast: Revenues ($bn) AGR (%), 2010-2017
Table 5.6 Global Zyvox Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 5.7 Global Canesten Market Forecast: Revenues ($bn) AGR (%), 2011-2017
Table 5.8 Global Canesten Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 5.9: Global Valtrex Market Forecast: Revenues ($bn) AGR (%), 2010-2017
Table 5.10 Global Valtrex Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 5.11 Global Bactroban Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 5.12 Global Lamisil Market Forecast: Revenues ($Bn) AGR (%), CAGR (%), 2016-2028
Table 5.13 Global Others Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 6.1 Global Acne Drugs Market by Drugs Class: Revenue ($bn), and Market Share (%), 2017
Table 6.2 Global Acne Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
Table 6.3 Global Acne Drugs Market by Drugs Class: CAGR (%), 2018-2022, 2022-2028, 2018-2028
Table 6.4 Global Epiduo Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 6.5 Global Solodyn Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 6.6 Global Claravis Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 6.7 Global Aczone Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 6.8 Global Differin Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 6.9 Global Absorica/ Epirus Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 6.10 Global Ziana Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 6.11 Global Doryx Market Forecast: Revenues ($Bn) AGR (%), CAGR (%), 2016-2028
Table 6.12 Global Others Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 7.1 Global Dermatitis Drugs Market by Drugs Class: Revenue ($bn), and Market Share (%), 2017
Table 7.2 Global Dermatitis Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
Table 7.3 Global Dermatitis Drugs Market by Drugs Class: CAGR (%), 2018-2022, 2022-2028, 2018-2028
Table 7.4 Global Bepanthen/ Bepanthol Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 7.5 Global Elocon Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 7.6 Global Protopic Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 7.7 Global Dermovate Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 7.8 Others Dermatitis Drugs Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 8.1 Global Dermatological Drugs Market by Region: Revenue ($bn), 2016 and 2017
Table 8.2 Global Dermatological Drugs Market Forecast, by Region: Revenues ($ bn), AGR (%), CAGR (%), 2016-2028
Table 8.3 Global Dermatological Drugs Market by Region: CAGR (%), 2018-2022, 2022-2028, 2018-2028
Table 8.4 Global Dermatological Drugs Market by Region: CAGR (%), 2018-2022, 2022-2028, 2018-2028
Table 9.1 North America Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
Table 9.2 North America Dermatological Drugs Market Forecast, By Country: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
Table 9.3 U.S. Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
Table 9.4 Canada Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
Table 10.1 Global Dermatological Drugs Market by Country/Sub-region: Revenue ($bn) and Market Share (%), 2017
Table 10.2 Europe Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
Table 10.3 Europe Dermatological Drugs Market Forecast, By Country: Revenues ($ bn), AGR (%), CAGR (%), 2016-2028
Table 10.4 Europe Dermatological Drugs Market by Country/Sub-region: CAGR (%), 2018-2022, 2022-2028, 2018-2028
Table 10.5 Germany Dermatological Drugs Market Forecast, 2016-2028 ($bn, AGR %, CAGR %)
Table 10.6 France Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
Table 10.7 U.K. Dermatological Drugs Market Forecast, 2016-2028 ($bn, AGR %, CAGR %)
Table 10.8 Italy Dermatological Drugs Market Forecast, 2016-2028 ($bn, AGR %, CAGR %)
Table 10.9 Spain Dermatological Drugs Market Forecast, 2016-2028 ($bn, AGR %, CAGR %)
Table 10.10 Rest of Europe Dermatological Drugs Market Forecast, 2016-2028 ($bn, AGR %, CAGR %)
Table 11.1 Asia-Pacific Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
Table 11.2 Asia-Pacific Dermatological Drugs Market Forecast, By Country: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
Table 11.3 China Dermatological Drugs Market Forecast, 2016-2028 ($bn, AGR %, CAGR %)
Table 11.4 Japan Dermatological Drugs Market Forecast, 2016-2028 ($bn, AGR %, CAGR %)
Table 11.5 India Dermatological Drugs Market Forecast, 2016-2028 ($bn, AGR %, CAGR %)
Table 11.6 Rest of Asia-Pacific Dermatological Drugs Market Forecast, 2016-2028 ($ bn, AGR %, CAGR %)
Table 12.1 Latin America Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
Table 12.2 Latin America Dermatological Drugs Market Forecast, By Country: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
Table 12.3 Brazil Dermatological Drugs Market Forecast, 2016-2028 ($bn, AGR %, CAGR %)
Table 12.4 Mexico Dermatological Drugs Market Forecast, 2016-2028 ($bn, AGR %, CAGR %)
Table 12.5 Rest of Latin America Dermatological Drugs Market Forecast, 2016-2028 ($bn, AGR %,

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report